Document is current
Any future updates will be listed below
-
Authors
Zou, Xiaoping https://orcid.org/0000-0003-4147-7051
Nie, Shuang
Cao, Jing
Shi, Mengyue
Schuck, Kathleen
Shi, Zhao
Zhang, Lingling
Li, Hongzhen
Sun, Yifeng
Fang, Chao
Hu, Jingxiong
Niu, Yiqi
Yu, Yuanyuan
Zhang, Zhiheng
Li, Chao
Hu, Mingyue
Wang, Lei
Jiang, Kuirong https://orcid.org/0000-0002-2849-5450
Lu, Zipeng
Akkan, Jan
Raulefs, Susanne
Kahlert, Christoph
Roth, Susanne https://orcid.org/0000-0002-5136-4686
Herr, Ingrid
Wan, Yuan
Mihaljevic, Andre
Qian, Xuetian
Zhang, Qi https://orcid.org/0000-0002-6096-0690
Wang, Maggie Haitian https://orcid.org/0000-0003-1223-4595
Kleeff, Jörg
Friess, Helmut
Gu, Zuguang
Michalski, Christoph W.
Shen, Shanshan https://orcid.org/0009-0000-7889-5674
- License Information
-
More Information
Article History
Received: 16 April 2025
Revised: 6 July 2025
Accepted: 30 July 2025
First Online: 8 August 2025
Competing interests
: The authors declare no competing interests.
: Clinical samples used in this study were approved by the Ethics Committee of the Technical University Munich (approval number: 80/17S) and the Ethics Committee of the Affiliated Drum Tower Hospital of Nanjing University (approval number: 2019-015-01). All mouse experiments and procedures were approved by the Institutional Animal Care and Use Committee of the Technical University of Munich (approval numbers: 55.2-1-54-2532-197-2016, ROB-55.2-2532.Vet_02-17-83), which address the ARRIVE guidelines. All procedures involving transgenic mice were performed in accordance with the Office of Laboratory Animal Welfare and German Federal Animal Protection Laws. BALB/c nu/nu athymic mice were approved by the Animal Care and Use Committee of the Nanjing Drum Tower Hospital (approval number: 20180102). All methods were performed in accordance with the relevant guidelines and regulations.
